European Science Foundation aims to strengthen 'regenerative medicine'

Stem cells are the body's 'master cells' that have not yet been programmed to perform a specific function. Most tissues have their own supply of stem cells, and it is becoming clear that if these cells can be given the appropriate biochemical instructions, they can 'differentiate' into new tissue. In this way, for example, stem cells could be seeded into damaged heart muscle to repair it.

Regenerative medicine has many advantages over more conventional ways of repairing or replacing damaged tissues or organs. Because the stem cells are taken from the person being treated, there are no problems with the body's immune system recognising the cells as 'foreign' and attempting to reject them, something that is still a problem with organ transplantation, for example.

To help ensure that Europe retains its competitive edge in the field, the ESF has launched REMEDIC, a research networking programme in regenerative medicine (13 May 2008). For the next five years a steering committee of 13 of Europe's leading specialists in regenerative medicine will organise a series of meetings and workshops to bring together experts to share ideas and develop new collaborations.

"I think this network will be very important to allow scientists in the field to share and disseminate information," says Professor Yrjö Konttinen, of Biomedicum Helsinki in Finland, who chairs the steering committee. "The network is open, so we will be in contact with many different organisations with an interest in the field. We want to meet people, establish joint collaborations with existing programmes and we will also be seeking funding for new initiatives."

REMEDIC will concentrate on the potential of a particular type of cell in the body called mesenchymal stromal cells. These can be obtained from fat tissue and coaxed to differentiate into a range of cell types, including bone, cartilage and muscle. Once the cells are in the relevant tissue, their growth and proliferation can be protected by biomaterials, which are structures implanted into the body that can guide the growth of the new tissue.

REMEDIC's first workshop is planned for mid-August in Helsinki, and a call for short term and exchange visits will be launched in late 2008. REMEDIC is a Research Networking Programme managed by the European Medical Research Councils (EMRC) at the European Science Foundation.

Source: European Science Foundation

Adult stem cell breakthrough
(PhysOrg.com) -- The first tissue-engineered trachea (windpipe), utilising the patient's own stem cells, has been successfully transplanted into a young woman with a failing airway. The bioengineered trachea immediately provided the patient with a normally functioning airway, thereby saving her life.
Japanese clone mouse from frozen cell, aim for mammoths
Japanese scientists said Tuesday they had created a mouse from a dead cell frozen for 16 years, taking a step in the long impossible dream of bringing back extinct animals such as mammoths.
First use of DNA fingerprinting to identify viable embryos
Fertility researchers have used DNA fingerprinting for the first time to identify which embryos have implanted after in vitro fertilisation (IVF) and developed successfully to result in the births of healthy babies. The technique, combined with sampling cells from blastocysts (the very early embryo) before implantation in the womb, opens the way to pin-pointing a handful of genes that could be used to identify those blastocysts most likely to result in a successful pregnancy.
Test of maturity for stem cells
Stem cells are extremely versatile: They can develop in 220 different ways, transforming themselves into a correspondingly diverse range of specialized body cells. Biologists and medical scientists plan to make use of this differentiation ability to selectively harvest cardiac, skin or nerve cells for the treatment of different diseases.
New type of drug shrinks primary breast cancer tumors significantly in just 6 weeks
A drug that targets the cell surface receptors that play an important role in many types of cancer can bring about significant tumour regression in breast cancer after only six weeks of use, a scientist told the 6th European Breast Cancer Conference (EBCC-6) today. Dr. Angel Rodriguez, from the Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, USA, said that the work demonstrated for the first time that the tyrosine kinase inhibitor lapatinib could decrease tumour-causing breast cancer stem cells in the primary breast cancers of women receiving neoadjuvant treatment (treatment given before the primary surgery for the disease).
Computation to unravel how genes are regulated and shed light on how cells become different
A closer alliance between computational and experimental researchers is needed to make progress towards one of biology’s most challenging goals, understanding how epigenetic marks contribute to regulation of gene expression. This emerged from a recent workshop organised by the European Science Foundation (ESF), “Computational Approaches to the Role of Epigenetic Marks in Transcription Regulation”.
An unexpected way to cause leukemia
Leukaemia – cancer of blood or bone marrow – is caused by mutations that allow defective blood cells to accumulate and displace healthy blood. To devise effective therapies it is crucial to know which mutations cause leukaemia and which cell type gives rise to leukaemic cells.
Stem cell research aims to tackle Parkinson's disease
Scientists in Sweden are developing new ways to grow brain cells in the laboratory that could one day be used to treat patients with Parkinson’s disease, an international conference of biologists organised by the European Science Foundation (ESF) was told last week.

European Science Foundation aims to strengthen 'regenerative medicine'

Related stories:

News discussion: